Henry Chan

975 total citations
37 papers, 414 citations indexed

About

Henry Chan is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Henry Chan has authored 37 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 11 papers in Molecular Biology and 11 papers in Hematology. Recurrent topics in Henry Chan's work include Multiple Myeloma Research and Treatments (10 papers), Lymphoma Diagnosis and Treatment (9 papers) and Cancer Treatment and Pharmacology (6 papers). Henry Chan is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Lymphoma Diagnosis and Treatment (9 papers) and Cancer Treatment and Pharmacology (6 papers). Henry Chan collaborates with scholars based in New Zealand, United States and Australia. Henry Chan's co-authors include Juli Feigon, Yaqiang Wang, Jiansen Jiang, Z. Hong Zhou, Lukas Sušac, Ritwika Basu, Donna Reece, Richard J. Milne, Christine I. Chen and Ronald A. Malt and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Henry Chan

34 papers receiving 406 citations

Peers

Henry Chan

PHYSI

ONCOL

HEMAT

PFM

Amy Dresen United States

Han Zhu China

Adnan Khosravi Iran

Wataru Saitoh Japan

Yangfeng Ding China

Bingni Chen China

C. Ronald Scott United States

Jean‐Michel Planquois France

Thomas Scambler United Kingdom

Amina Barakat Morocco

Amy Dresen United States

Henry Chan

222 ×1.2

50 ×0.4

PHYSI

137 ×1.6

ONCOL

17 ×0.2

HEMAT

64 ×1.1

PFM

Citations per year, relative to Henry Chan Henry Chan (= 1×) peers Amy Dresen

Countries citing papers authored by Henry Chan

Since Specialization

Citations

This map shows the geographic impact of Henry Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry Chan more than expected).

Fields of papers citing papers by Henry Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry Chan. The network helps show where Henry Chan may publish in the future.

Co-authorship network of co-authors of Henry Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Henry Chan. A scholar is included among the top collaborators of Henry Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry Chan. Henry Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chan, Henry, et al.. (2025). An Overview of the Current Scientific Evidence on the Biological Properties of Abelmoschus esculentus (L.) Moench (Okra). Foods. 14(2). 177–177. 2 indexed citations

Klein, Oliver, Matteo S. Carlino, Craig Underhill, et al.. (2024). 713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial. Annals of Oncology. 35. S546–S547. 5 indexed citations

Klein, Oliver, Matteo S. Carlino, Michelle Brown, et al.. (2024). 282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer. Annals of Oncology. 35. S119–S119. 2 indexed citations

Klein, Oliver, Bo Gao, Henry Chan, et al.. (2024). 998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study. Annals of Oncology. 35. S679–S680. 1 indexed citations

Teh, Benjamin W., Gemma Reynolds, Monica A. Slavin, et al.. (2023). Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma. Internal Medicine Journal. 53(8). 1469–1477. 5 indexed citations

Moore, Elizabeth, Hilary Blacklock, Cameron Wellard, et al.. (2022). Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma Myeloma & Leukemia. 22(8). e762–e769.

Merriman, Eileen, et al.. (2022). Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant. Clinical Lymphoma Myeloma & Leukemia. 22(11). 835–840. 1 indexed citations

Zhang, Jesse, et al.. (2021). Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma. Journal of Geriatric Oncology. 13(4). 505–510. 1 indexed citations

Merriman, Eileen, et al.. (2021). Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal. Thrombosis and Haemostasis. 122(7). 1096–1103. 5 indexed citations

10.

Tam, Constantine S., Ian M. Morison, David Simpson, et al.. (2020). A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology. 52(2). 167–178. 12 indexed citations

11.

Chan, Henry, et al.. (2020). Electronic FRAIL score may predict treatment outcomes in older adults with myeloma. Journal of Geriatric Oncology. 12(4). 515–520. 3 indexed citations

12.

Chan, Henry, et al.. (2019). Frontline treatment of elderly non transplant‐eligible multiple myeloma patients using CyBorD with or without thalidomide‐based consolidation: a retrospective multi‐centre analysis of real‐world data. British Journal of Haematology. 187(4). 470–477. 14 indexed citations

13.

Jiang, Jiansen, Yaqiang Wang, Lukas Sušac, et al.. (2018). Structure of Telomerase with Telomeric DNA. Cell. 173(5). 1179–1190.e13. 103 indexed citations

14.

Chan, Henry, Manjula Maganti, Esther Masih‐Khan, et al.. (2018). Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation. Clinical Lymphoma Myeloma & Leukemia. 18(3). 225–234. 8 indexed citations

15.

Cao, Qin, Woo Shik Shin, Henry Chan, et al.. (2018). Inhibiting amyloid-β cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design. Nature Chemistry. 10(12). 1213–1221. 50 indexed citations

16.

Chan, Henry, Christine I. Chen, & Donna Reece. (2017). Current Review on High-Risk Multiple Myeloma. Current Hematologic Malignancy Reports. 12(2). 96–108. 19 indexed citations

17.

Chan, Henry, Yaqiang Wang, & Juli Feigon. (2017). Progress in Human andTetrahymenaTelomerase Structure Determination. Annual Review of Biophysics. 46(1). 199–225. 32 indexed citations

18.

Chan, Henry, et al.. (2016). Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients. Leukemia & lymphoma. 57(11). 2584–2592. 7 indexed citations

19.

Nguyen, Tinh Thi, et al.. (2011). The physiology of the normal human breast: an exploratory study. Journal of Physiology and Biochemistry. 67(4). 621–627. 4 indexed citations

20.

Chia, David, Paul I. Terasaki, Henry Chan, & Miyuki Ozawa. (1991). Binding of IgG to B cell via HLA molecules. Tissue Antigens. 37(2). 49–55. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact